Trevi Therapeutics, Inc. (TRVI) - Form 8-K Summary
Business Context and Reporting Period
Trevi Therapeutics, Inc., a Delaware corporation, filed this Current Report on Form 8-K on August 7, 2025. The filing announces the Company's financial results for the quarter ended June 30, 2025. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the press release (Exhibit 99.1) but are not detailed within the body of this Form 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the incorporated press release for comparative financial analysis.
Guidance, Outlook, and Risks
This Form 8-K serves as a notification of the results announcement. It does not contain specific guidance, management commentary, risk factors, or details on contingencies and unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 financial figures including cash position and burn rate.
- Verify the Company's cash runway and any recent capital raise activities mentioned in the press release.
- Check for updates on clinical trial progress or regulatory milestones for Trevi's drug candidates.
- Confirm if the press release includes updated financial guidance or changes to the operating plan.